BOUL: Sales declined but margins improved; restructuring aims to boost profitability

About this update from Boule Diagnostics Ab

Q2 2024 saw a 2.5% sales decline but improved gross margin to 43.1%. Adjusted operating profit rose, though non-recurring costs led to a net loss. Strategic restructuring and cost optimization are underway to enhance margins and efficiency. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Boule Diagnostics Ab